Answers are grounded in this paper and cite their sources.
* Abbreviations: GH = : growth hormone • IGF-I = : insulin-like growth factor-I Growth hormone (GH) is administered by subcutaneous injections. Common complications have been limited to bruising, a development of a hematoma at the injection sites.1 2 However, local atrophy or dimpling and hypertrophy or lumps have been observed occasionally. The purpose of this report is to present a boy who developed significant hypertrophy of the subcutaneous tissue mass at the local site of GH injections in his abdomen. J. T. was a 12.5-year-old healthy boy with short stature. Linear growth was noted to decline at 3 years of age. Since then, he continued to grow slow; in comparison with the growth observed on his older sibling and peers of the same age group (no documentation is available). At the time of presentation he was below two standards deviations from the mean. At the time of his birth the mother was 32 years old and his father was 48 years of age. The mother's stature was 160 cm; the father's was 173 cm. His 18-year-old brother weighed 3.2 kg at birth. His growth and development were normal and his stature was 168 cm. There is no history of consanguinity, short stature, or delayed adolescence in the family. He was the 2.35-kg, 48.5-cm product of a term gestation. His mother was G2, P1, and suffers from epilepsy. Medications used during gestation included Tegretol, Mysoline, …
No takes yet. Share an insight, caveat, or question.
Ruvalcaba et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: